Teva Pharmaceutical Industries Stock Price, News & Analysis (NYSE:TEVA)

$20.90 +0.10 (+0.48 %)
(As of 02/18/2018 03:56 AM ET)
Previous Close$20.90
Today's Range$20.75 - $21.10
52-Week Range$10.85 - $37.94
Volume14.77 million shs
Average Volume21.07 million shs
Market Capitalization$21.40 billion
P/E Ratio-1.21
Dividend Yield4.07%
Beta0.59

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:TEVA
CUSIPN/A
Phone+972-3-9267267

Debt

Debt-to-Equity Ratio1.91%
Current Ratio0.86%
Quick Ratio0.66%

Price-To-Earnings

Trailing P/E Ratio-1.20809248554913
Forward P/E Ratio9.05
P/E Growth1.8

Sales & Book Value

Annual Sales$22.39 billion
Price / Sales0.95
Cash Flow$6.30 per share
Price / Cash3.32
Book Value$14.88 per share
Price / Book1.40

Profitability

Trailing EPS($17.30)
Net Income$-16,265,000,000.00
Net Margins-72.66%
Return on Equity16.43%
Return on Assets4.91%

Miscellaneous

Employees56,960
Outstanding Shares1,016,000,000

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries declared a quarterly dividend on Thursday, November 2nd. Investors of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its earnings results on Thursday, February, 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.14. The firm earned $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm's revenue for the quarter was down 15.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

When will Teva Pharmaceutical Industries make its next earnings announcement?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.

Where is Teva Pharmaceutical Industries' stock going? Where will Teva Pharmaceutical Industries' stock price be in 2018?

27 analysts have issued 1 year price targets for Teva Pharmaceutical Industries' shares. Their predictions range from $11.00 to $43.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $21.22 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:

  • 1. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
  • 2. According to Zacks Investment Research, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. " (1/12/2018)
  • 3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
  • 4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 65,701,193 shares, a decrease of 6.7% from the January 12th total of 70,392,179 shares. Based on an average daily trading volume, of 16,651,324 shares, the days-to-cover ratio is presently 3.9 days. Approximately 6.5% of the shares of the stock are short sold.

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:

  • Sol J. Barer Ph.D., Chairman of the Board (Age 69)
  • Kaare Schultz, President, Chief Executive Officer (Age 56)
  • Michael McClellan, Chief Financial Officer, Executive Vice President
  • Iris Beck-Codner, Executive Vice President - Global Brand & Communications (Age 52)
  • Richard Daniell, Executive Vice President - European Commercial
  • Carlo de Notaristefani, Executive Vice President - Global Operations (Age 59)
  • Sven Dethlefs Ph.D., Executive Vice President - Global Marketing & Portfolio
  • Hafrun Fridriksdottir, Executive Vice President - Global R&D (Age 55)
  • Gianfranco Nazzi, Executive Vice President - Growth Markets Commercial
  • Brendan O'Grady, Executive Vice President - North America Commercial

Who owns Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (7.82%), ALLERGAN PLC (6.80%), ALLERGAN PLC (6.80%), ALLERGAN PLC (3.90%), Northern Cross LLC (2.18%) and Abrams Capital Management L.P. (1.94%). View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Who sold Teva Pharmaceutical Industries stock? Who is selling Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alliancebernstein L.P., Macquarie Group Ltd., Abrams Capital Management L.P., Quantitative Investment Management LLC, Barrow Hanley Mewhinney & Strauss LLC, Schroder Investment Management Group and Clal Insurance Enterprises Holdings Ltd. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Who bought Teva Pharmaceutical Industries stock? Who is buying Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Franklin Resources Inc., OppenheimerFunds Inc., Commerzbank Aktiengesellschaft FI, Teachers Advisors LLC, Millennium Management LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management and Harel Insurance Investments & Financial Services Ltd.. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy Teva Pharmaceutical Industries stock?

Shares of Teva Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of Teva Pharmaceutical Industries stock can currently be purchased for approximately $20.90.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $21.40 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis. Teva Pharmaceutical Industries employs 56,960 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 Basel St., P.O. Box 3190, PETAH TIKVA, 49131, Israel. The company can be reached via phone at +972-3-9267267 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  945 (Vote Outperform)
Underperform Votes:  807 (Vote Underperform)
Total Votes:  1,752
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.962.072.042.25
Ratings Breakdown: 7 Sell Rating(s)
14 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
15 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
15 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
16 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.22$21.32$21.47$34.86
Price Target Upside: 13.23% upside0.76% downside67.86% upside104.57% upside

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Price Target History for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018Wells Fargo & CoReiterated RatingSellMediumView Rating Details
2/11/2018Credit Suisse GroupUpgradeNeutral -> Outperform$20.00 -> $23.00MediumView Rating Details
2/9/2018Bank of AmericaLower Price TargetUnderperform -> Underperform$17.00 -> $16.00LowView Rating Details
2/9/2018Leerink SwannLower Price TargetUnderweight -> Underperform$17.00 -> $16.00HighView Rating Details
2/9/2018Deutsche BankLower Price TargetHold -> Hold$20.00 -> $18.00MediumView Rating Details
2/9/2018GabelliDowngradeBuy -> Hold$19.00MediumView Rating Details
2/9/2018Piper Jaffray CompaniesDowngradeNeutral -> Underweight$11.00MediumView Rating Details
2/9/2018Royal Bank of CanadaUpgradeUnderperform -> Sector Perform$18.00MediumView Rating Details
2/8/2018Cantor FitzgeraldSet Price TargetHold$18.00MediumView Rating Details
2/8/2018OppenheimerReiterated RatingHoldMediumView Rating Details
2/8/2018Maxim GroupReiterated RatingHoldMediumView Rating Details
2/2/2018BTIG ResearchDowngradeNeutral -> Sell$17.00LowView Rating Details
1/25/2018Susquehanna BancsharesReiterated RatingPositive -> Positive$22.00 -> $24.00MediumView Rating Details
1/11/2018Goldman Sachs GroupBoost Price TargetBuy$20.00 -> $25.00HighView Rating Details
1/9/2018MizuhoUpgradeNeutral -> Buy$19.12 -> $23.00N/AView Rating Details
1/4/2018CitigroupUpgradeNeutral -> Buy$24.00LowView Rating Details
12/15/2017Morgan StanleyUpgradeUnderweight -> Equal Weight$18.00MediumView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$16.00HighView Rating Details
11/13/2017JPMorgan Chase & Co.DowngradeNeutral -> Underweight$11.48 -> $11.00N/AView Rating Details
10/25/2017Evercore ISISet Price TargetBuy$38.00N/AView Rating Details
10/20/2017BarclaysSet Price TargetHold$21.00 -> $19.00N/AView Rating Details
10/4/2017CowenReiterated RatingMarket Perform$30.00 -> $18.00N/AView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/12/2017Jefferies GroupLower Price TargetHold$21.00 -> $18.50HighView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Earnings by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018        
2/8/2018Q4 17$0.77$0.91$5.29 billion$5.46 billionViewListenView Earnings Details
11/2/2017Q3 2017$1.03$0.95ViewN/AView Earnings Details
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
11/2/2010Q3 2010$1.27$1.30ViewN/AView Earnings Details
7/26/2010Q2 2010$1.04$1.08ViewN/AView Earnings Details
5/4/2010Q1 2010$0.89$0.92ViewN/AView Earnings Details
2/16/2010Q4 2009$0.95$0.94ViewN/AView Earnings Details
11/3/2009Q3 2009$0.88$0.89ViewN/AView Earnings Details
7/28/2009Q2 2009$0.80$0.83ViewN/AView Earnings Details
5/5/2009Q1 2009$0.67$0.72ViewN/AView Earnings Details
2/17/2009Q4 2008$0.73$0.76ViewN/AView Earnings Details
11/6/2008Q3 2008$0.69$0.72ViewN/AView Earnings Details
7/29/2008Q2 2008$0.64$0.65ViewN/AView Earnings Details
5/6/2008Q1 2008$0.63$0.64ViewN/AView Earnings Details
2/12/2008Q4 2007$0.66$0.69ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

Current Year EPS Consensus Estimate: $2.31 EPS
Next Year EPS Consensus Estimate: $2.51 EPS

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Most Recent Dividend:12/12/2017
Annual Dividend:$0.72
Dividend Yield:3.44%
Dividend Growth:-14.40% (3 Year Average)
Payout Ratio:-4.16% (Trailing 12 Months of Earnings)
31.17% (Based on This Year's Estimates)
28.69% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/2/2017quarterly$0.092.74%11/27/201711/28/201712/12/2017
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries (NYSE TEVA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

Source:
DateHeadline
Teva Pharmaceutical Industries (TEVA) Upgraded at ValuEngineTeva Pharmaceutical Industries (TEVA) Upgraded at ValuEngine
www.americanbankingnews.com - February 17 at 6:34 PM
Its Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to ... - Investorplace.comIt's Time to Add Teva Pharmaceutical Industries Ltd (ADR) Stock to ... - Investorplace.com
investorplace.com - February 17 at 8:04 AM
After the Bell: Dow Soars 300 Points as Utilities Lead Stocks HigherAfter the Bell: Dow Soars 300 Points as Utilities Lead Stocks Higher
finance.yahoo.com - February 16 at 8:06 AM
Tevas stock soars after Warren Buffetts Berkshire discloses new stakeTeva's stock soars after Warren Buffett's Berkshire discloses new stake
www.marketwatch.com - February 15 at 5:30 PM
Cramer: Im shocked by Buffetts Berkshire making a bet on worst-of-the-worst TevaCramer: I'm shocked by Buffett's Berkshire making a bet on worst-of-the-worst Teva
finance.yahoo.com - February 15 at 5:30 PM
Why Teva Pharmaceutical Industries, SolarEdge Technologies, and Overstock.com Jumped TodayWhy Teva Pharmaceutical Industries, SolarEdge Technologies, and Overstock.com Jumped Today
finance.yahoo.com - February 15 at 5:30 PM
Here's What Warren Buffett, Other Top Investors Are Buying And SellingHere's What Warren Buffett, Other Top Investors Are Buying And Selling
finance.yahoo.com - February 15 at 5:30 PM
Cisco Systems and Teva jump while NetApp slumpsCisco Systems and Teva jump while NetApp slumps
finance.yahoo.com - February 15 at 5:30 PM
Teva shares drop 3% after rival generic product approved and launched - MarketWatchTeva shares drop 3% after rival generic product approved and launched - MarketWatch
www.marketwatch.com - February 15 at 8:14 AM
3 Stocks to Watch on Thursday: NetApp Inc. (NTAP), Sun Life Financial Inc (SLF) and Teva Pharmaceutical Industries ... - Investorplace.com3 Stocks to Watch on Thursday: NetApp Inc. (NTAP), Sun Life Financial Inc (SLF) and Teva Pharmaceutical Industries ... - Investorplace.com
investorplace.com - February 15 at 8:14 AM
4 Reasons For The Berkshire Investment In Teva - Seeking Alpha4 Reasons For The Berkshire Investment In Teva - Seeking Alpha
seekingalpha.com - February 15 at 8:14 AM
Behind The Idea: Tevas Tribulations (Podcast) - Seeking AlphaBehind The Idea: Teva's Tribulations (Podcast) - Seeking Alpha
seekingalpha.com - February 15 at 8:14 AM
Deteriorating Credit Metrics Make Teva A Sell - Seeking Alpha - Seeking AlphaDeteriorating Credit Metrics Make Teva A Sell - Seeking Alpha - Seeking Alpha
seekingalpha.com - February 15 at 8:14 AM
3 Stocks to Watch on Thursday: NetApp Inc. (NTAP), Sun Life Financial Inc (SLF) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA)3 Stocks to Watch on Thursday: NetApp Inc. (NTAP), Sun Life Financial Inc (SLF) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
investorplace.com - February 15 at 8:03 AM
Teva Pharma (TEVA) Announces U.S. Launch of QVAR RediHaler Inhalation AerosolTeva Pharma (TEVA) Announces U.S. Launch of QVAR RediHaler Inhalation Aerosol
www.streetinsider.com - February 14 at 8:17 AM
 Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Post Quarterly Sales of $4.84 Billion Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Post Quarterly Sales of $4.84 Billion
www.americanbankingnews.com - February 14 at 6:16 AM
Teva Pharmaceutical Industries Ltd (TEVA) Short Interest UpdateTeva Pharmaceutical Industries Ltd (TEVA) Short Interest Update
www.americanbankingnews.com - February 14 at 4:34 AM
Is Teva Pharma's Restructuring Plan Actually 'More Reasonable'?Is Teva Pharma's Restructuring Plan Actually 'More Reasonable'?
finance.yahoo.com - February 13 at 3:34 PM
Teva shares drop 3% after rival generic product approved and launchedTeva shares drop 3% after rival generic product approved and launched
finance.yahoo.com - February 13 at 3:34 PM
Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis DrugTeva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug
finance.yahoo.com - February 13 at 3:34 PM
Teva Pharmaceutical Industries (TEVA) Receives "Sell" Rating from Wells Fargo & CoTeva Pharmaceutical Industries (TEVA) Receives "Sell" Rating from Wells Fargo & Co
www.americanbankingnews.com - February 13 at 11:12 AM
Are Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) Interest Costs Too High?Are Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) Interest Costs Too High?
finance.yahoo.com - February 13 at 8:13 AM
Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical Industries and Pfizer Inc.Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical Industries and Pfizer Inc.
finance.yahoo.com - February 13 at 8:13 AM
Teva planned for 2nd generic Copaxone to enter market in 2018Teva planned for 2nd generic Copaxone to enter market in 2018
finance.yahoo.com - February 13 at 8:13 AM
Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2017Teva Pharmaceutical Industries Ltd (TEVA) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 12 at 3:35 PM
Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Earnings of $0.74 Per ShareTeva Pharmaceutical Industries Ltd (TEVA) Expected to Post Earnings of $0.74 Per Share
www.americanbankingnews.com - February 12 at 11:06 AM
Teva Pharmaceutical Industries Ltd (ADR) Stock Is About to SpikeTeva Pharmaceutical Industries Ltd (ADR) Stock Is About to Spike
investorplace.com - February 12 at 10:47 AM
Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation AerosolTeva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol
finance.yahoo.com - February 12 at 8:10 AM
Teva Pharmaceutical Industries (TEVA) Upgraded to Outperform at Credit Suisse GroupTeva Pharmaceutical Industries (TEVA) Upgraded to Outperform at Credit Suisse Group
www.americanbankingnews.com - February 11 at 8:40 PM
Teva Pharmaceutical Industries (TEVA) Upgraded at Royal Bank of CanadaTeva Pharmaceutical Industries (TEVA) Upgraded at Royal Bank of Canada
www.americanbankingnews.com - February 11 at 12:12 AM
Piper Jaffray Companies Downgrades Teva Pharmaceutical Industries (TEVA) to UnderweightPiper Jaffray Companies Downgrades Teva Pharmaceutical Industries (TEVA) to Underweight
www.americanbankingnews.com - February 10 at 10:54 PM
Gabelli Lowers Teva Pharmaceutical Industries (TEVA) to HoldGabelli Lowers Teva Pharmaceutical Industries (TEVA) to Hold
www.americanbankingnews.com - February 10 at 9:48 PM
Deutsche Bank Analysts Give Teva Pharmaceutical Industries (TEVA) a $18.00 Price TargetDeutsche Bank Analysts Give Teva Pharmaceutical Industries (TEVA) a $18.00 Price Target
www.americanbankingnews.com - February 10 at 5:48 PM
Teva Pharmaceutical Industries Limited 2017 Q4 - Results - Earnings Call SlidesTeva Pharmaceutical Industries Limited 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 10 at 3:36 PM
Contrasting Teva Pharmaceutical Industries (TEVA) & Innocoll (INNL)Contrasting Teva Pharmaceutical Industries (TEVA) & Innocoll (INNL)
www.americanbankingnews.com - February 10 at 1:20 PM
Teva Pharmaceutical Industries (TEVA) Stock Rating Lowered by ValuEngineTeva Pharmaceutical Industries (TEVA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - February 9 at 11:12 PM
Leerink Swann Lowers Teva Pharmaceutical Industries (TEVA) Price Target to $16.00Leerink Swann Lowers Teva Pharmaceutical Industries (TEVA) Price Target to $16.00
www.americanbankingnews.com - February 9 at 10:04 PM
Teva Pharmaceutical Industries (TEVA) PT Lowered to $16.00 at Bank of AmericaTeva Pharmaceutical Industries (TEVA) PT Lowered to $16.00 at Bank of America
www.americanbankingnews.com - February 9 at 6:10 PM
Teva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook WarningTeva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook Warning
www.wsj.com - February 9 at 3:43 PM
[$$] Teva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook Warning[$$] Teva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook Warning
finance.yahoo.com - February 9 at 3:43 PM
Teva Announces Launch of a Generic Version of Syprine® in the United StatesTeva Announces Launch of a Generic Version of Syprine® in the United States
finance.yahoo.com - February 9 at 3:43 PM
Teva Pharmaceutical Industries Ltd (ADR) Announces the Launch of Generic Equivalents to SyprineTeva Pharmaceutical Industries Ltd (ADR) Announces the Launch of Generic Equivalents to Syprine
finance.yahoo.com - February 9 at 3:43 PM
Teva Nailed With S&P DowngradeTeva Nailed With S&P Downgrade
finance.yahoo.com - February 9 at 3:43 PM
Francisco Garcia Parames Cobas Asset Management Comments on Fourth Quarter 2017Francisco Garcia Parames' Cobas Asset Management Comments on Fourth Quarter 2017
finance.yahoo.com - February 9 at 3:43 PM
Teva Reports 2017 Full Year and Fourth Quarter Financial Results - Business Wire (press release)Teva Reports 2017 Full Year and Fourth Quarter Financial Results - Business Wire (press release)
www.businesswire.com - February 9 at 8:17 AM
Teva shares plummet 10% after downbeat 2018 guidance - MarketWatchTeva shares plummet 10% after downbeat 2018 guidance - MarketWatch
www.marketwatch.com - February 9 at 8:17 AM
Teva Pharmaceutical warns on 2018 profits citing US market, Copaxone - CNBCTeva Pharmaceutical warns on 2018 profits citing US market, Copaxone - CNBC
www.cnbc.com - February 9 at 8:17 AM
Teva Pharmaceutical Industries (TEVA) Q4 2017 Results - Earnings Call Transcript - Seeking AlphaTeva Pharmaceutical Industries (TEVA) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 9 at 8:17 AM
Today’s Research Reports on Stocks to Watch: Mylan and Teva PharmaceuticalToday’s Research Reports on Stocks to Watch: Mylan and Teva Pharmaceutical
finance.yahoo.com - February 9 at 8:17 AM
Will Teva Pharmaceutical's Pain Be Mylan's Gain?Will Teva Pharmaceutical's Pain Be Mylan's Gain?
finance.yahoo.com - February 9 at 8:17 AM

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.